Custom dCas9-VPR Overexpressing Cell Line Development Service
The dCas9-VPR overexpressing cell line is a genetically engineered model where a nuclease-deactivated Cas9 (dCas9) is fused with the VPR transcriptional activator (VP64, p65, Rta). Guided by sgRNA, dCas9-VPR binds specific genomic sites to robustly activate target gene expression without cutting DNA. This system is widely applied in CRISPRa-related research for gene function analysis, drug screening, and disease modeling. Creative Biolabs offers customized, high-quality dCas9-VPR cell line development using trusted CRISPR technology. We ensure stable expression, high efficiency, and reproducibility—empowering clients to explore gene regulation and accelerate therapeutic discovery with confidence.
dCas9-VPR Activation System Introduction
Figure 1. Neuronal differentiation using CRISPRa.1
The dCas9-VPR system combines sequence-specific DNA targeting with transcriptional activation. The dCas9 component is derived from Cas9 but contains mutations that abolish nuclease activity. As a result, dCas9 can still be guided to a genomic sequence by an sgRNA, but it does not create DNA cleavage at the target site.
The VPR module is a potent transcriptional activation domain composed of three activation elements:
| Component | Function in Gene Activation |
|---|---|
| VP64 | A strong transcriptional activator that helps recruit transcriptional machinery |
| p65 | A transcription activation domain associated with NF-κB signaling-related transcriptional activation |
| Rta | A viral transactivation domain that further strengthens transcriptional activation |
| dCas9 scaffold | Directs the VPR activator to sgRNA-defined genomic loci without DNA cutting |
| sgRNA | Determines target specificity by guiding dCas9-VPR to selected promoter or regulatory sequences |
Why dCas9-VPR Outperforms Alternative CRISPRa Systems?
While multiple CRISPRa (CRISPR activation) systems exist, the VPR system offers distinct architectural and functional advantages:
- Simplified Design: The dCas9-VPR system does not require a modified sgRNA for effective activation, simplifying the design process significantly. Other systems, such as dCas9-SAM, incorporate modified sgRNAs with two RNA hairpin aptamers that bind to dimers of the bacteriophage MS2 coat proteins.
- Potent Upregulation: The VPR system demonstrated superior activation in various cell models, including U-2 OS and MCF7 cells.
- High Efficiency: The dCas9-VPR transactivating module shows high efficiency across different species and cell types.
The Critical Need for Stable Overexpressing Cell Lines in Gene Therapy Research
While the dCas9-VPR system is highly potent, it presents significant delivery challenges due to its large payload size. Because of its size (5.8 kb), dCas9-VPR exceeds the genome packaging capacity of recombinant adeno-associated viral (rAAV) vectors. These rAAV vectors are currently the gold standard for gene delivery to native tissues and for gene therapy.
- Streamlined Protocols: This setup allows researchers to focus solely on corresponding gRNA delivery, streamlining workflows and enhancing experimental reproducibility.
- Alleviating Packaging Limits: In some researches using delivery systems such as AAV and LNP, using Cas9-expressing cells alleviates packaging constraints and boosts editing efficiency.
Introduction of Custom dCas9-VPR Overexpressing Cell Line Development Service
The dCas9-VPR overexpressing cell line is a powerful genetic tool for precise gene activation without causing DNA cleavage. dCas9 is a deactivated form of Cas9 that binds specific DNA sites without introducing double-strand breaks. When fused with VPR, a strong transcriptional activator composed of VP64, p65, and Rta, it forms a complex that can be directed by sgRNAs to target promoters and activate gene expression effectively. Unlike traditional CRISPR/Cas9 systems, dCas9 serves as a DNA-bound scaffold, recruiting the VPR module to drive transcription in a programmable, non-disruptive way. This makes it an ideal platform for CRISPRa-based research. Establishing a stable dCas9-VPR overexpressing cell line enables durable and consistent gene activation, supporting a wide range of applications such as functional genomics, pathway analysis, cell fate reprogramming, drug discovery, and disease modeling—all without altering the genome.
How Custom dCas9-VPR Overexpressing Cell Line Development Service Can Assist Your Project
At Creative Biolabs, our custom dCas9-VPR overexpressing cell line development service is committed to delivering high-quality monoclonal cell lines tailored to your research needs. Each single-cell clone is rigorously screened and validated to ensure stable integration and high-level expression of dCas9-VPR. We perform comprehensive quality control procedures, including genomic PCR and RT-qPCR for integration verification and expression quantification, Western blotting to confirm protein expression levels, and mycoplasma testing to ensure cell line cleanliness and biosafety. These robust, mycoplasma-free monoclonal lines offer reliable and reproducible gene activation, significantly enhancing the accuracy and consistency of downstream applications such as functional genomics, drug screening, and pathway analysis - regardless of whether you are using commercial CRISPRa libraries or fully customized sgRNA libraries.
- Stable dCas9-VPR Cell Pool Development
- Monoclonal dCas9-VPR Overexpressing Cell Line Development
- Inducible dCas9-VPR Expression Cell Line Development
- Cell-Type-Specific dCas9-VPR Engineering
- CRISPRa Functional Validation Support
Common Challenges and Creative Biolabs' Solutions
Challenge 1: Low Engineering Efficiency in Difficult Cell Types
Some cell lines are resistant to transduction, sensitive to selection, or difficult to expand after engineering. This can reduce development success and delay downstream experiments.
Creative Biolabs' Solution:
We optimize delivery conditions, selection strategies, and recovery procedures based on cell type. For challenging cells, we can adjust transduction parameters, selection timing, and culture conditions to improve the chance of generating a stable dCas9-VPR expressing population.
Challenge 2: Heterogeneous dCas9-VPR Expression
Mixed cell populations may contain cells with different dCas9-VPR expression levels, leading to variable gene activation outcomes.
Creative Biolabs' Solution:
We offer monoclonal cell line development and clone screening to identify stable, high-performing clones. This helps reduce experimental variability and supports reproducible CRISPRa studies.
Challenge 3: Expression Without Functional Activation
A cell line may express dCas9-VPR, but poor sgRNA design, chromatin context, or insufficient activator performance may limit target gene activation.
Creative Biolabs' Solution:
We can provide optional functional validation using selected sgRNAs and target gene expression assays. This helps confirm that the final cell line is suitable for CRISPRa experiments.
Quality Control and Validation
Reliable CRISPRa experiments require a high-quality dCas9-VPR cell model. Creative Biolabs integrates multiple quality control steps to support reproducibility and confidence.
| QC Item | Purpose | Typical Readout |
|---|---|---|
| Genomic PCR | Confirms integration of the dCas9-VPR expression cassette | Positive integration signal |
| RT-qPCR | Measures dCas9-VPR transcript expression | Relative mRNA expression level |
| Western blotting | Confirms dCas9-VPR protein expression | Protein band detection |
| Antibiotic selection check | Confirms stable maintenance under selection | Surviving selected population |
| Clone expansion assessment | Evaluates growth and recovery | Growth curve or expansion observation |
| Mycoplasma testing | Ensures cell line cleanliness | Negative mycoplasma result |
| Optional functional activation assay | Confirms CRISPRa activity | Target gene upregulation |
| Optional stability assessment | Evaluates expression over passages | Sustained expression profile |
Workflow of Custom dCas9-VPR Overexpressing Cell Line Development Service
Figure. 2 Workflow of our custom dCas9-VPR overexpressing cell line development service.
Selection Guide: Which dCas9-VPR Cell Line Format Is Right for Your Project?
| Project Need | Recommended Format | Why It Fits |
|---|---|---|
| Fast pilot study | Stable dCas9-VPR cell pool | Faster turnaround and suitable for initial feasibility testing |
| Long-term repeated assays | Monoclonal dCas9-VPR cell line | Improved reproducibility and reduced population heterogeneity |
| Pooled CRISPRa screening | Validated monoclonal or highly characterized stable pool | Supports consistent activator expression across sgRNA library experiments |
| Time-controlled activation | Inducible dCas9-VPR cell line | Enables activation at selected experimental time points |
| Sensitive cell model | Customized engineering workflow | Helps balance delivery efficiency, viability, and phenotype preservation |
| Functional validation required | dCas9-VPR line plus sgRNA activation testing | Confirms practical activation performance before downstream use |
| Drug response study | Monoclonal line with functional validation | Improves consistency across treatment conditions |
| Disease pathway modeling | Cell-type-specific dCas9-VPR line | Supports activation studies in relevant biological background |
Example Research Scenarios We Support
Scenario 1: Activating a Candidate Therapeutic Target
A client has identified a candidate gene that may improve a disease-relevant phenotype when upregulated. Creative Biolabs develops a stable dCas9-VPR cell line and introduces sgRNAs targeting the candidate gene promoter. Gene activation is confirmed by RT-qPCR, and the client proceeds to downstream phenotype analysis.
Scenario 2: Building a CRISPRa Screening Platform
A research team wants to perform a pooled CRISPRa screen to identify genes that confer drug resistance. Creative Biolabs generates a monoclonal dCas9-VPR overexpressing line, validates expression, confirms functional activation, and supports sgRNA library delivery planning.
Scenario 3: Modeling Gain-of-Function Biology
A client needs to mimic disease-associated gene upregulation in a cancer cell model. Creative Biolabs develops a stable dCas9-VPR line and validates activation of selected pathway genes, enabling downstream studies of proliferation, survival, and drug sensitivity.
Scenario 4: Studying Differentiation Regulators
A researcher wants to activate transcription factors involved in cell fate transition. Creative Biolabs develops an inducible dCas9-VPR expressing cell line to allow time-controlled gene activation during a differentiation protocol.
What You Receive
When partnering with Creative Biolabs for custom dCas9-VPR overexpressing cell line development, clients may receive a complete package tailored to their project needs.
Deliverables may include:
- Stable dCas9-VPR overexpressing cell pool or monoclonal cell line
- Project-specific development strategy
- dCas9-VPR expression construct information
- Cell engineering and selection summary
- Clone screening data
- Genomic integration confirmation results
- RT-qPCR expression data
- Protein expression validation results
- Mycoplasma testing result
- Optional CRISPRa functional validation data
- Recommended cell culture and handling information
- Cell stock delivery or cell banking support
- Technical consultation for downstream CRISPRa use
Advantages of Custom dCas9-VPR Overexpressing Cell Line Development Service
- Wide Cell Type Compatibility - Efficiently applies dCas9-VPR across various cell types, including immortalized lines, stem cells, and primary cells, to meet different research demands.
- Flexible Yet Focused Workflow - Customizable development ensures smooth integration of dCas9-VPR, simplifying your downstream experiments.
- High-Throughput Capable - Designed for large-scale screening, supporting both commercial CRISPRa libraries and custom sgRNA sets.
- Stringent Quality Control - Validated for stable expression and reliable performance of dCas9-VPR, ensuring consistent gene activation.
- Comprehensive Technical Support - Full project support with expert guidance and responsive service, ensuring success at every step of your dCas9-VPR workflow.
Customer Reviews
Frequently Asked Questions (FAQ)
Q: How does dCas9-VPR differ from traditional gene overexpression?
A: Traditional methods randomly integrate an exogenous cDNA sequence driven by a constitutive promoter, which can lead to unnatural, excessively high protein levels and potential toxicity. Furthermore, traditional methods cannot accurately replicate native alternative splicing. The dCas9-VPR system, by contrast, targets the endogenous gene promoter directly. This upregulates the transcription of the gene in its native chromosomal context, maintaining natural splice variants and yielding more physiologically relevant gain-of-function data.
Q: Can I perform genome-wide CRISPRa screening with your custom dCas9-VPR cell lines?
A: Yes. Our extensively validated cell lines are highly scalable for high-throughput use and are well-suited for pooled CRISPR screens. They are fully compatible with a wide range of commercial CRISPR activation libraries and can be customized for specific sgRNA collections. By utilizing our pre-validated dCas9-VPR lines, you bypass the need for dual-vector co-transduction during the screening phase, drastically reducing background noise and improving the Multiplicity of Infection (MOI) control for your gRNA library.
Q: How do you confirm the functionality of the dCas9-VPR system in the finalized cell line?
A: Beyond standard molecular verifications (such as genome PCR, RT-qPCR, and Western blot), we execute rigorous expression and functionality assays to ensure transcriptional activation efficiency. We introduce control gRNAs targeting well-characterized endogenous genes and measure the resulting transactivation levels compared to wild-type controls. This guarantees that the integrated dCas9-VPR module is not only highly expressed but also biologically active and ready-to-use.
Q: Is the dCas9-VPR system safe to use in gene therapy research models?
A: Yes. The nuclease-inactive Cas9 (dCas9) binds target DNA without cutting it. Therefore, it enables targeted transcriptional activation of endogenous genes without genomic disruption or irreversible DNA damage. This is highly advantageous for therapeutic models where permanent gene knockout is impractical or introduces unwanted effects.
Q: What is the delivery format of the final cell line?
A: Creative Biolabs delivers high-quality, mycoplasma-free monoclonal cell lines. The final deliverables include cryopreserved vials of the validated clonal cell line, comprehensive quality control documentation detailing genomic integration, expression profiling, functional assays, and optimal culturing protocols.
Get Started with Your Project Today
Accelerate your functional genomics mapping and gene therapy development with confidence. By providing ready-to-use Cas9-overexpressing cell lines, Creative Biolabs helps streamline your CRISPR workflows, reduce delivery complexity, and improve experimental reproducibility. Whether you are conducting simple targeted gene activation studies, genome-wide high-throughput screening, or advanced therapeutic target discovery, we are your trusted partner. To discuss your project or request a quote, please contact us today—we are here to support your success from concept to results.
Reference
- Liu S, Striebel J, Pasquini G, et al. Neuronal cell-type engineering by transcriptional activation. Frontiers in Genome Editing, 2021, 3: 715697. https://doi.org/10.3389/fgeed.2021.715697 Distributed under Open Access license CC BY 4.0, without modification.
